Replacement Myocardial Fibrosis in Patients With Mitral Valve Prolapse: Relation to Mitral Regurgitation, Ventricular Remodeling, and Arrhythmia.

Arrhythmias, Cardiac Echocardiography / methods Female Fibrosis / pathology Humans Male Middle Aged Mitral Valve Insufficiency Mitral Valve Prolapse / physiopathology Myocardium / pathology Ventricular Remodeling
arrhythmias, cardiac fibrosis mitral valve insufficiency mitral valve prolapse prognosis

Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
04 05 2021
Historique:
pubmed: 13 3 2021
medline: 16 9 2021
entrez: 12 3 2021
Statut: ppublish

Résumé

Mitral valve prolapse (MVP) is a frequent disease that can be complicated by mitral regurgitation (MR), heart failure, arterial embolism, rhythm disorders, and death. Left ventricular (LV) replacement myocardial fibrosis, a marker of maladaptive remodeling, has been described in patients with MVP, but the implications of this finding remain scarcely explored. We aimed at assessing the prevalence, pathophysiological and prognostic significance of LV replacement myocardial fibrosis through late gadolinium enhancement (LGE) by cardiac magnetic resonance in patients with MVP. Four hundred patients (53±15 years of age, 55% male) with MVP (trace to severe MR by echocardiography) from 2 centers, who underwent a comprehensive echocardiography and LGE cardiac magnetic resonance, were included. Correlates of replacement myocardial fibrosis (LGE+), influence of MR degree, and ventricular arrhythmia were assessed. The primary outcome was a composite of cardiovascular events (cardiac death, heart failure, new-onset atrial fibrillation, arterial embolism, and life-threatening ventricular arrhythmia). Replacement myocardial fibrosis (LGE+) was observed in 110 patients (28%; 91 with myocardial wall including 71 with basal inferolateral wall, 29 with papillary muscle). LGE+ prevalence was 13% in trace-mild MR, 28% in moderate MR, and 37% in severe MR, and was associated with specific features of mitral valve apparatus, more dilated LV and more frequent ventricular arrhythmias (45% versus 26%, LV replacement myocardial fibrosis is frequent in patients with MVP; is associated with mitral valve apparatus alteration, more dilated LV, MR grade, and ventricular arrhythmia; and is independently associated with cardiovascular events. These findings suggest an MVP-related myocardial disease. Last, cardiac magnetic resonance provides additional information to echocardiography in MVP.

Sections du résumé

BACKGROUND
Mitral valve prolapse (MVP) is a frequent disease that can be complicated by mitral regurgitation (MR), heart failure, arterial embolism, rhythm disorders, and death. Left ventricular (LV) replacement myocardial fibrosis, a marker of maladaptive remodeling, has been described in patients with MVP, but the implications of this finding remain scarcely explored. We aimed at assessing the prevalence, pathophysiological and prognostic significance of LV replacement myocardial fibrosis through late gadolinium enhancement (LGE) by cardiac magnetic resonance in patients with MVP.
METHODS
Four hundred patients (53±15 years of age, 55% male) with MVP (trace to severe MR by echocardiography) from 2 centers, who underwent a comprehensive echocardiography and LGE cardiac magnetic resonance, were included. Correlates of replacement myocardial fibrosis (LGE+), influence of MR degree, and ventricular arrhythmia were assessed. The primary outcome was a composite of cardiovascular events (cardiac death, heart failure, new-onset atrial fibrillation, arterial embolism, and life-threatening ventricular arrhythmia).
RESULTS
Replacement myocardial fibrosis (LGE+) was observed in 110 patients (28%; 91 with myocardial wall including 71 with basal inferolateral wall, 29 with papillary muscle). LGE+ prevalence was 13% in trace-mild MR, 28% in moderate MR, and 37% in severe MR, and was associated with specific features of mitral valve apparatus, more dilated LV and more frequent ventricular arrhythmias (45% versus 26%,
CONCLUSIONS
LV replacement myocardial fibrosis is frequent in patients with MVP; is associated with mitral valve apparatus alteration, more dilated LV, MR grade, and ventricular arrhythmia; and is independently associated with cardiovascular events. These findings suggest an MVP-related myocardial disease. Last, cardiac magnetic resonance provides additional information to echocardiography in MVP.

Identifiants

DOI: 10.1161/CIRCULATIONAHA.120.050214 PMID: 33706538
pubmed: 33706538
doi: 10.1161/CIRCULATIONAHA.120.050214
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1763-1774

Auteurs

Anne-Laure Constant Dit Beaufils (AL)

Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Olivier Huttin (O)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Antoine Jobbe-Duval (A)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).

Thomas Senage (T)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Biostatistic Department, Université de Nantes, France (T.S.).

Laura Filippetti (L)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Nicolas Piriou (N)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).

Caroline Cueff (C)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Clément Venner (C)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Damien Mandry (D)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Jean-Marc Sellal (JM)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Solena Le Scouarnec (S)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Romain Capoulade (R)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Marie Marrec (M)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).

Aurélie Thollet (A)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Marine Beaumont (M)

Gabriella Hossu (G)

CIC-IT, U1433, CHRU de Nancy, France; INSERM U1254, Imagerie Adaptative Diagnostique et Interventionnelle, Université de Lorraine, France (G.H.).

Claire Toquet (C)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Jean-Baptiste Gourraud (JB)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Jean-Noël Trochu (JN)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Karine Warin-Fresse (K)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).

Pierre-Yves Marie (PY)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Jean-Jacques Schott (JJ)

Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Jean-Christian Roussel (JC)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Jean-Michel Serfaty (JM)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Christine Selton-Suty (C)

Service de Cardiologie, Institut Lorrain du Cœur et des Vaisseaux, CHU de Nancy, France (O.H., L.F., C.V., D.M., J.-M. Sellal, P.-Y.M., C.S.-S.).

Thierry Le Tourneau (T)

CHU de Nantes, Université de Nantes, l'institut du thorax, CIC 1413, France (A.J.-D., T.S., N.P., C.C., M.M., A.T., C.T., J.-B.G., J.-N.T., K.W.-F., J.-C.R., J.-M. Serfaty, T.L.T.).
Université de Nantes, CHU de Nantes, CNRS, INSERM, l'institut du thorax, France (A.-L.C.D.B., C.C., S.L.S., R.C., A.T., C.T., J.-B.G., J.-N.T., J.-J.S., J.-C.R., J.-M. Serfaty, T.L.T.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Troubles du rythme cardiaque › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic cardiovasculaire › Tests de la fonction cardiaque › Échocardiographie › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Valvulopathies › Insuffisance mitrale › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Valvulopathies › Prolapsus des valves cardiaques › Prolapsus de la valve mitrale › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › Tissus › Muscles › Muscle strié › Myocarde › Replacement Myocardial Fibrosis in Patients...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Fonction ventriculaire › Remodelage ventriculaire › Replacement Myocardial Fibrosis in Patients...